July 2008 Newsletter   #88  (v. 9, 7)
PCNG

Prostate Cancer Networking Group
of
 Greater Cincinnati
PCNG (pcngcincinnati.org) is a chapter of USTOO (www.ustoo.com)
Founder: Bob Kanter - Convener: Tom Young – Newsletter: 450 copies this issue - Editor: Kees DeJong
Facilitators: Stan Moczydlowski: 8/’03; Steven Plymire: 9/’03; Jerry Glenn: 1/’04; Jack Ramsay: 5/’04;
Dick Fencl: 5/’05;: Jerry Bryan: 2/’07; Librarian: Stan Moczydlowski; Reviewers: Frits Roos, Daniel White

      Telephone contacts:

751-6888 Kees DeJong: 1996 (56), PSA 24, GS 9; IAD; EBRT+Brachy, IAD, AD, ketoconazole+HC, Leukine, estradiol patches; Taxotere, carboplatin, Avastin, Emcyt


871-3844
Carol Cappiello

528-2769 Gordon Huntley:1999, PSA 4, GS 9; RP & Orchiectomy

272-1820 Dick Fencl: 2003, PSA 14, GS 6, EBRT+Brachy

 

733-5745 Bill Riggs: 1995, 
PSA 33, GS 6; RP, EBRT, AD 

221-6736 John Hoffmann: 1997, PSA 5, GS 6; RP, EBRT 

 

984-3343 Tom Young: 2002, PSA 7.8, GS 6; RP

19/20xx: year of diagnosis;  PSA: Prostate Specific Antigen;  GS: Gleason Score;  RP: Radical Prostatectomy;  EBRT: External Beam Radiation Therapy;  Brachy: Brachytherapy ('seeds'), and  AD: Hormonal Therapy: Androgen Deprivation
Carol Cappiello is a partner of a PC patient; she will be happy to answer any questions about PC,
in particular from other partners


Our 20th APC Meeting will be held before the Large Meeting
Men with Advanced Prostate Cancer, please, come!!
From 5.30 to 6.30 pm; bring your spouses/partners, some food will be served.

The next Large Group Meeting Will Be Held on Wednesday, July 30th
Women Are Very Much Welcome!!
6.30--7.00 p.m.: hospitality and networking    
7.00--7.30 p.m.: new members and sharing
7.30 p.m.:

PART 2:
Great Cost of Cancer Treatment Requires
Knowledge of Medicaid: The New Medicaid Rules.
Also: Trusts for Beneficiaries.

Mark S. Reckman, Esq.

Mark Reckman has been with Wood & Lamping since 1977 as a law clerk and since 1979 as an attorney.  He has served in every management role at Wood & Lamping, including Managing Partner. Mr. Reckman sits on the Good Samaritan Hospital Foundation Board and is also Chairman of the Board of Columbia Savings Bank. In 2006 Mark was named as a Super Lawyer for the State of Ohio by Law and Politics magazine.

8.30--9.00 p.m.: hospitality and networking


Next Small Discussion Group Meeting (for Men only) will be held on
Wednesday, August 13th, from 7.00-9.00 pm at the Wellness Community


Mark Reckman will present part 2 of his talk

   Mark Reckman did such a great job last month; he’s coming back by popular demand. Please get in touch with him with questions he can address this month.
   His contact information is as follows:
Msreckman@woodlamping.com; Phone: (513)852-6054; Fax: (513) 852-6087.
   In August, our speaker is Alan V. Safdi, M.D,. of Greater Cincinnati Gastroenterology Associates, Inc. Alan is a prostate cancer survivor and will discuss his work-out routine and nutritional habits since being treated. More on this to come….

   Tom Young


Hormonal Treatment versus Watchful Waiting

Are you in the late seventies and diagnosed with prostate cancer? Your best option might be to do nothing, also known as conservative management or watchful waiting. That is the conclusion in an article in the July 2008 issue of the Journal of the American Medical Association:


Lu-Yao GL et al.: JAMA. 2008 Jul 9;300(2):173-81. Survival following primary androgen deprivation therapy among men with localized prostate cancer.

CONTEXT: Despite a lack of data, increasing numbers of patients are receiving primary androgen deprivation therapy (PADT) as an alternative to surgery, radiation, or conservative management for the treatment of localized prostate cancer. OBJECTIVE: To evaluate the association between PADT and survival in elderly men with localized prostate cancer.
DESIGN, SETTING, AND PATIENTS: A population-based cohort study of 19,271 men aged 66 years or older receiving Medicare who did not receive definitive local therapy for clinical stage T1-T2 prostate cancer. These patients were diagnosed in 1992-2002 within predefined US geographical areas, with follow-up through December 31, 2006, for all-cause mortality and through December 31, 2004, for prostate cancer-specific mortality. ...
RESULTS: Among patients with localized prostate cancer (median age, 77 years), 7867 (41%) received PADT, and 11,404 were treated with conservative management, not including PADT. During the follow-up period, there were 1560 prostate cancer deaths and 11,045 deaths from all causes. Primary androgen deprivation therapy was associated with lower 10-year prostate cancer-specific survival (80.1% vs 82.6% ...) and no increase in 10-year overall survival (30.2% vs 30.3% ...) compared with conservative management. However, in a prespecified subset analysis, PADT use in men with poorly differentiated cancer was associated with improved prostate cancer-specific survival (59.8% vs 54.3% ...) but not overall survival (17.3% vs 15.3% ...).
CONCLUSION: Primary androgen deprivation therapy is not associated with improved survival among the majority of elderly men with localized prostate cancer when compared with conservative management.


Does a Diagnosis of Prostate Cancer Change Enrollment in the Managed Care Programs of Medicare?


Satisfaction in either Medicare or Managed Care appears similar, though in the 2 years after diagnosis, prostate cancer patients were slightly less likely to disenroll from Medicare Managed Care than their matched cancer-free peers.
Later this year Medicare patients will have a chance to disenroll from Medicare into a Managed Care program. The following, from a July 2008 article, in the J. Nat. Cancer Inst., is a must reading for those contemplating a change in care.

Elkin EB et al.: J Natl Cancer Inst. 2008 Jul 8, 1013-21.
“Disenrollment From Medicare Managed Care Among Beneficiaries With and Without a Cancer Diagnosis.”

   “Managed care was introduced to the Medicare program with the hope that competition between plans would help to control escalating costs, expand preventive services, and improve coordination of care. During the 1990s, the number of Medicare beneficiaries participating in managed care increased substantially, from 1.3 million (4% of beneficiaries) in 1990 to 6.3 million (16% of beneficiaries) in 2000. Although the availability of plans and beneficiary participation vary geographically, more than 80% of Medicare beneficiaries now have access to at least one managed care plan.
   Managed care organizations generally aim to improve disease prevention and management while containing the costs of care. However, the mechanisms that they use to achieve these goals, such as primary care gatekeeping, provider networks, and higher cost sharing for out-of-network services, may restrict enrollees’ access to specific providers and create barriers or disincentives to the use of expensive services. These mechanisms may deter enrollment and retention of individuals with chronic or complex diseases, particularly conditions for which access to specialized treatment centers or physicians is perceived as advantageous. Numerous studies have found that Medicare managed care plans tend to attract and retain beneficiaries who are younger and healthier and have lower pre-enrollment medical expenditures than beneficiaries in the traditional Medicare indemnity insurance (ie, "fee-for-service") program . Survey results indicate that voluntary disenrollment from a Medicare managed care plan may reflect beneficiaries’ perceptions of poor quality of care, impaired access to services or providers, or overall dissatisfaction with their plans.
   With more than 55% of all cancer diagnoses and 70% of all cancer deaths occurring in people aged 65 years or older, the experience of cancer patients in the Medicare program is of particular concern. Cancer patients and survivors typically require regular visits with specialists, coordination of care among multiple providers, and frequent testing to monitor disease. For the past decade, there has been increasing emphasis on the value of provider expertise in treating complex medical conditions such as cancer. Because managed care plans may constrain enrollees’ choice of providers, participation in Medicare managed care may feel especially restrictive to enrollees with cancer. Problems with access have been correlated with beneficiary dissatisfaction and may also prompt disenrollment.

The percent of beneficiaries with prostate cancer (solid line) and without prostate cancer (dashed line) who remained continuously enrolled in Medicare managed care after a cancer diagnosis..

   However, Medicare managed care plans often provide benefits that are not available in the traditional fee-for-service segment of Medicare. Perhaps more importantly, because participation in a Medicare managed care plan generally entails lower out-of-pocket health care spending than fee-for-service Medicare, enrollees may be reluctant to disenroll when facing a serious illness that requires substantial medical care utilization. Our objective was to compare rates of voluntary disenrollment to fee-for-service Medicare among Medicare managed care enrollees with and without a cancer diagnosis.
   In this population-based analysis of Medicare managed care enrollees, a cancer diagnosis did not precipitate voluntary disenrollment from a Medicare managed care plan to fee-for-service Medicare. In the 2 years following cancer diagnosis, beneficiaries with cancer were less likely to disenroll than their matched cancer-free peers. This result was evident across a spectrum of different cancers and in nearly all strata of age, sex, race, and geographic region. Although characteristics of Medicare managed care plans influenced the likelihood of disenrollment, they did not meaningfully confound or modify the relationship between cancer status and disenrollment.
   We examined voluntary disenrollment from Medicare managed care to fee-for-service Medicare presuming that the frequency with which seniors exercise their option to disenroll signals their dissatisfaction with Medicare managed care, which in turn reflects actual or perceived problems with access to care or quality of care in their plans. If voluntary disenrollment from Medicare managed care is, in fact, beneficiaries’ way of "voting with their feet," then our results suggest that enrollees facing a serious, potentially life-threatening illness are as satisfied with Medicare managed care, if not more so, than their cancer-free peers. This conclusion is consistent with surveys that have compared Medicare beneficiaries in managed-care plans with those in fee-for-service Medicare and found similar levels of overall satisfaction.
   Our results may also be related to reduced cost sharing for Medicare-covered services and the availability of outpatient prescription drug coverage in Medicare managed care plans. During the study period, Medicare beneficiaries lacking employer-sponsored supplemental insurance faced deductibles and coinsurance payments for most covered health services (including most physician-administered chemotherapy, covered under Part B of Medicare) and the full costs of outpatient prescription drugs that were not covered under Part B. For these beneficiaries, enrolling in a Medicare managed care plan was generally a lower-cost alternative to purchasing an expensive supplemental "Medigap" policy. Several studies have shown that the absence or removal of a prescription drug benefit was associated with a greater likelihood of disenrollment in Medicare managed care plans. Surveys of Medicare beneficiaries have found greater financial access to care and greater satisfaction with costs among Medicare managed care enrollees than beneficiaries with traditional fee-for-service coverage. Medicare managed care enrollees may also have remained in their plans if they were concerned about obtaining a supplemental insurance policy upon returning to fee-for-service Medicare. For beneficiaries who did not enroll in a managed care plan when they first became eligible for Medicare, resumption of a self-purchased supplemental policy was not guaranteed.
   An alternative explanation for our findings is that after developing a serious illness, seniors may be less willing to make a change in insurance coverage, even if such a change would facilitate access to a broader choice of providers. A preference for the status quo, as described in the economic literature, has been observed in health insurance decisions and may be more common with increasing age. Substantial gaps in knowledge about the Medicare program in general and Medicare managed care plans in particular suggest a mechanism for enrollee inertia: beneficiaries may be especially reluctant to change their insurance enrollment if they do not fully understand their options.
   Breast, colorectal, prostate, and lung cancers are often treated by community-based physicians and do not necessarily require services that are available only at specialized centers. Therefore, even Medicare managed care plans that limit access to specific providers may still offer satisfactory care to patients with these common cancers. Positing that beneficiaries with cancers that are rarer or require more complex or less standardized treatment regimens might be more inclined to disenroll from Medicare managed care, we repeated our analyses in cohorts with non-Hodgkin lymphoma, acute leukemia, and soft-tissue sarcoma, and we found no effect of the cancer diagnosis on the likelihood of disenrollment. We also expected that disenrollment would be more common among enrollees diagnosed with advanced-stage cancer, for whom a generally poor prognosis may provoke a sense of urgency and a desire for specialty consultations and investigational therapies. However, we observed no difference in disenrollment by stage at diagnosis. Therefore, despite the array of mechanisms used by Medicare managed care plans to manage care and control costs, cancer patients may not feel so restricted in their choice of providers that they will leave managed care and return to traditional fee-for-service Medicare.
   Our findings have practical implications for Medicare beneficiaries, managed care plans, and policymakers. In an effort to improve continuity of care, stabilize the Medicare managed care market, and discourage beneficiaries from "gaming the system," the 2003 Medicare Modernization Act eliminated the opportunity to switch plans monthly and limited beneficiaries to an annual plan election followed by a brief period during which they could make one additional plan change. Although the new policy, implemented in 2006, resembles the annual open enrollment period commonly offered by employers who provide a choice of commercial insurance plans, the "lock-in" provision in Medicare has prompted concern that seniors receiving dissatisfactory or substandard care might suffer as a result of reduced choice. However, we did not observe an exodus of enrollees subsequent to cancer diagnosis during our study period, before 2006, when monthly opt-out was possible. Thus, the move from monthly to yearly open enrollment appears unlikely to be problematic for most Medicare managed care enrollees, including those with a serious illness.
   In addition to limiting the frequency of changes in plan enrollment, the Medicare Modernization Act encourages the expansion of Medicare managed care to include a wider array of plans and a larger number of beneficiaries, prompting concern about the quality of care in Medicare managed care, especially among vulnerable subgroups of the Medicare population. The adoption of increasingly sophisticated beneficiary-level risk adjustment methods for determining Medicare managed care payments may encourage plans to focus more on the needs of seriously ill beneficiaries and thus enhance services. Our results suggest that Medicare managed care enrollees with cancer are sufficiently satisfied with their care to remain in a managed care plan. Monitoring of access to care and quality of care, within both the fee-for-service and managed care segments of Medicare, remains a priority.”

The Am. Cancer Society, http://cancer.org, estimates that in 2008, in the USA, 186,320 new cases of prostate cancer will be diagnosed; 28,660 men will die of this disease = 15 % of the new cases. Compare this percentage with that for lung cancer: in 2007 213,380 new cases and 160,390 deaths = 75 % of the new cases, or pancreatic cancer: 37,170 new cases and 33,370 deaths = 90 % of the new cases

click on the underlined references in the HTML or PDF editions of this newsletter for additional information

google 
 ‘PCNG’

and find our Home Page, Newsletter Archive, and the page linking to 100+ Prostate Cancer Web Sites

PCNG: PROSTATE CANCER NETWORKING GROUP
of Greater Cincinnati
c/o The Wellness Community
4918 Cooper Road
Cincinnati, OH 45242